195 related articles for article (PubMed ID: 32467173)
1. PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Dougherty MI; Lehman CE; Spencer A; Mendez RE; David AP; Taniguchi LE; Wulfkuhle J; Petricoin EF; Gioeli D; Jameson MJ
Mol Cancer Res; 2020 Sep; 18(9):1392-1401. PubMed ID: 32467173
[TBL] [Abstract][Full Text] [Related]
2. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
[TBL] [Abstract][Full Text] [Related]
3. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
4. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
5. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
[TBL] [Abstract][Full Text] [Related]
6. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Cassell A; Freilino ML; Lee J; Barr S; Wang L; Panahandeh MC; Thomas SM; Grandis JR
Neoplasia; 2012 Nov; 14(11):1005-14. PubMed ID: 23226094
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
[TBL] [Abstract][Full Text] [Related]
8. Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro.
Khalil A; Jameson MJ
Horm Cancer; 2019 Feb; 10(1):11-23. PubMed ID: 30350263
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways.
Pickhard AC; Margraf J; Knopf A; Stark T; Piontek G; Beck C; Boulesteix AL; Scherer EQ; Pigorsch S; Schlegel J; Arnold W; Reiter R
BMC Cancer; 2011 Sep; 11():388. PubMed ID: 21896192
[TBL] [Abstract][Full Text] [Related]
11. Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
Jameson MJ; Taniguchi LE; VanKoevering KK; Stuart MM; Francom CR; Mendez RE; Beckler AD; Carlson HT; Thomas CY; Khalil AA
J Oral Pathol Med; 2013 Apr; 42(4):332-8. PubMed ID: 23106397
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.
Lehman CE; Khalil AA; Axelrod MJ; Dougherty MI; Schoeff SS; Taniguchi LE; Mendez RE; David AP; McGarey PO; Hubbard MA; Donaldson L; Frierson HF; Stelow EB; Bekiranov S; Wulfkuhle JD; Petricoin EF; Gioeli DG; Jameson MJ
Laryngoscope; 2020 Jun; 130(6):1470-1478. PubMed ID: 31433065
[TBL] [Abstract][Full Text] [Related]
13. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.
Shimizu R; Ibaragi S; Eguchi T; Kuwajima D; Kodama S; Nishioka T; Okui T; Obata K; Takabatake K; Kawai H; Ono K; Okamoto K; Nagatsuka H; Sasaki A
Int J Oncol; 2019 Jan; 54(1):283-294. PubMed ID: 30431077
[TBL] [Abstract][Full Text] [Related]
14. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
Lattanzio L; Milano G; Monteverde M; Tonissi F; Vivenza D; Merlano M; Lo Nigro C
Anticancer Drugs; 2016 Jul; 27(6):533-9. PubMed ID: 26982238
[TBL] [Abstract][Full Text] [Related]
16. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
[TBL] [Abstract][Full Text] [Related]
17. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
18. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
19. Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
Wu TK; Ou YC; Chen YP; Huang FM; Pan YR; Lee CJ
Anticancer Res; 2021 Aug; 41(8):3789-3799. PubMed ID: 34281838
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
